Insider filing · BNTC

Averill Master Fund, Ltd. bought $11.7M of Benitec Biopharma (BNTC)

Executed Mar 26 2025, disclosed Mar 28 2025, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Mar 28 2025), the stock returned -0.3% (delay-adjusted); from the execution session (Mar 26 2025), -7.9%. Derived: entry at the session's open, exit at the close 20 sessions later.

AL Averill Master Fund, Ltd. Director profile →

Averill Master Fund, Ltd. (Director) filed 3 Form 4 reports as a reporting entity in the past 24 months (3 purchases, 0 sales), most often in BNTC. Across 3 priced purchase filings, the average 21-session return was +3.2% from execution and +0.7% from disclosure (delay-adjusted; derived). The largest single filing was $11.7M of BNTC (900,000 sh across 2 lots, as filed), executed Mar 26 2025.

BNTC BNTC BNTC · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→